Figure S2 Found at: doi:10.1371/journal.pone.0004881.s004 (4.33 MB EPS) Acknowledgments We thank Dr. Xiu-hua ZHANG and Dr. Jin-gui MA for their assistance in tyrosine kinases assays; Dr. Min HUANG for COMET assay; Dr. Yi CHEN, Mrs. Li-juan LU and Mr. Yong XI for in vivo animal models. References 1. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655–1657. 2. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, et al. (1997) Rapamycin suppresses 59TOP mRNA translation through inhibition of p70s6k. Embo J 16: 3693–3704. 3. Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527–5541. 4. Maira SM, Voliva C, Garcia-Echeverria C (2008) Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 12: 223–238. 5. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918. 6. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, et al. (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252–261. 7. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508. 8. Ding H, Zhang C, Wu X, Yang C, Zhang X, et al. (2005) Novel indole alpha- methylene-gamma-lactones as potent inhibitors for AKT-mTOR signaling pathway kinases. Bioorg Med Chem Lett 15: 4799–4802. 9. Casamayor A, Morrice NA, Alessi DR (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342(Pt 2): 287–292. 10. Scheid MP, Marignani PA, Woodgett JR (2002) Multiple phosphoinositide 3- kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22: 6247–6260. 11. Nobes CD, Hawkins P, Stephens L, Hall A (1995) Activation of the small GTP- binding proteins rho and rac by growth factor receptors. J Cell Sci 108(Pt 1): 225–233. 12. Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179–183. 13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101. 14. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303–20312. 15. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, et al. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909–919. 16. Chiu MI, Katz H, Berlin V (1994) RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 91: 12574–12578. S9 Targets PI3K/mTOR/Tubulin Author Contributions Conceived and designed the experiments: LHM JD. Performed the experiments: CZ NY YZ. Analyzed the data: CZ NY LHM JD. Contributed reagents/materials/analysis tools: CY HsD MjW XWZ XS. Wrote the paper: CZ NY LHM JD. Molecular Modeling: CL HJ. 17. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, et al. (2006) Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 545–556. 18. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341–349. 19. Clute P, Pines J (1999) Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1: 82–87. 20. Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, et al. (2006) The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res 66: 951–959. 21. Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2: 1–17. 22. Bhattacharyya B, Wolff J (1974) Promotion of flurescence upon binding of colchicine to tubulin. Proc Natl Acad Sci U S A 71: 2627. 23. Wipf P, Halter RJ (2005) Chemistry and biology of wortmannin. Org Biomol Chem 3: 2053–2061. 24. Gastpar R, Goldbrunner M, Marko D, von Angerer E (1998) Methoxy- substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem 41: 4965–4972. 25. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, et al. (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271–6280. 26. Zhang C, Yang F, Zhang XW, Wang SC, Li MH, et al. (2006) Grateloupia longifolia polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC-1 endothelial cells. Br J Pharmacol 148: 741–751. 27. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, et al. (2006) Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69: 1226–1233. 28. Dulal Panda HPM, LeslieWilson (1999) Rapid treadmilling of brain microtu- bules freeof microtubule-associated proteins in vitro and its suppression by tau. 29. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, et al. (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744–1748. 30. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198–202. 31. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, et al. (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3- peptide and AMP-PNP. Nat Struct Biol 9: 940–944. 32. Henikoff S, Henikoff JG (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89: 10915–10919. 33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19: 1639–1662. PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4881